Publications in collaboration with researchers from Hospital Miguel Servet (3)

2019

  1. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance

    Haematologica, Vol. 104, Núm. 11, pp. 2249-2257

2009

  1. Análisis retrospectivo de la eficacia y la tolerabilidad de anagrelida en pacientes con trombocitemia esencial: Registro español de trombocitemia esencial

    Medicina Clinica, Vol. 133, Núm. 3, pp. 86-90

1993

  1. Interferon alpha 2a in the treatment of chronic myelogenous leukemia in chronic phase. Results of the Spanish group

    Leukemia and Lymphoma, Vol. 11, Núm. s1, pp. 175-179